News >

Rule Reflects on Continued Benefit With Ibrutinib in Relapsed/Refractory MCL

Danielle Ternyila
Published: Thursday, Feb 06, 2020

Simon Rule, MD, PhD, a professor of hematology at Plymouth University Medical School

Simon Rule, MD, PhD

The BTK inhibitor ibrutinib (Imbruvica) led to more favorable responses than chemotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL), according to 7.5 years of follow-up of pooled data from 3 clinical trials that were presented during the 2019 ASH Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication